Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen.

Douglas Ward, Wenbin Wei, John Buckels, Ahmad Taha, B Hegab, L Tariciotti, R Salih, Yi-Jun Qi, Ashley Martin, Philip Johnson

Research output: Contribution to journalArticle

4 Citations (Scopus)


BACKGROUND: There is an urgent need for biomarkers to detect pancreatic cancer in the early, potentially curable, stages. METHODS: We have used SELDI profiling to analyze serum from 75 patients with pancreatic cancer and 61 patients with nonmalignant pancreaticobiliary diseases. RESULTS: A peak in the SELDI spectra corresponding to a 53 residue fragment of the alpha-chain of fibrinogen is remarkably elevated in approximately 50% of the cancer patients. In addition, fibrinogen degradation products were measured using the DR-70 assay. The areas under the receiver operating characteristic curves for the SELDI-detected fibrinogen fragment, DR-70 and CA19-9 were 0.65, 0.75 and 0.86, respectively. Class prediction models using combinations of these markers did not increase the area under the receiver operating characteristic curve compared with CA19-9. The novel fibrinogen fragment was not elevated to the same extent in other malignancies but was elevated in some patients with benign pancreatic disease. CONCLUSION: Both the SELDI-detected fragment of fibrinogen and DR-70 are significantly elevated in the serum of pancreatic cancer patients. However, they do not seem to improve pancreatic cancer detection over CA19-9 alone.
Original languageEnglish
Pages (from-to)1358-1363
Number of pages6
JournalEuropean Journal of Gastroenterology & Hepatology
Issue number11
Publication statusPublished - 15 Jun 2010


  • pancreas
  • biomarker
  • fibrinogen
  • proteomics
  • cancer


Dive into the research topics of 'Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen.'. Together they form a unique fingerprint.

Cite this